We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.50 | -0.40% | 1,634.00 | 1,634.00 | 1,634.50 | 1,647.00 | 1,634.00 | 1,638.50 | 570,477 | 11:28:48 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.70 | 67.5B |
From Apr 2019 to Apr 2024
Rory Gallivan
LONDON--GlaxoSmithKline PLC (GSK.LN) said Thursday a study of its Mekinist and Tafinlar drugs showed favorable results compared with another treatment in patients with the skin cancer Melanoma.
The drug company said a committee recommended the study be stopped early having "demonstrated an overall survival benefit for the trametinib and dabrafenib combination compared to vemurafenib that crossed the pre-specified efficacy stopping boundary."
Shares at 1311 GMT, up 4 pence, or 0.3%, at 1,548 pence, valuing the company at GBP75 billion ($128.5 billion).
Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
